EDOMED

EdoPharma is a Swiss clinical-stage biopharmaceutical company, formerly known as Edomed Biotech, dedicated to developing innovative oncology treatments. The company's lead asset is tinostamustine (EDO-S101), a first-in-class small molecule that integrates the mechanisms of a histone deacetylase (HDAC) inhibitor and a DNA-damaging alkylating agent into a single entity. This dual-action approach is designed to overcome drug resistance in hematologic malignancies such as multiple myeloma and various lymphomas. EdoPharma's broader pipeline includes EDO-B776, an immunocytokine targeting the tumor microenvironment, and EDO-B151, a pan-Polo-like kinase inhibitor, both aimed at treating advanced solid tumors.